The same fraction was also shown to inhibit the production of pro-angiogenic factors (VEGF, IL-8 CXCL8, CXCL12), in addition to proliferation, invasion and migration of human and murine colon cancer cells (HT-29, HCT-116, CT-26) or of prostate cancer cells (PC-3, DU-145, LNCaP), thus again linking anti-proliferative and ant-angiogenic effects together [115,116]. The gene discussed is CXCL8; the disease is prostate cancer.